<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-02-04</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-02-04 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">106</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-02-05 04:14</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-29">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/29</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-30">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/30</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-31">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/31</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-02-01">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">02/01</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-02">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">02/02</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-03">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">02/03</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-04">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">02/04</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥è¡Œä¸šåŠ¨æ€èšç„¦äºç›‘ç®¡æ”¿ç­–ä¸é‡ç£…è¯ç‰©å¸‚åœºè¡¨ç°ã€‚FDAç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’é‡æ–°æˆæƒè‡³2029å¹´ï¼Œä¸ºå„¿ç§‘æ–°è¯ç ”å‘æ³¨å…¥å¼ºå¿ƒå‰‚ï¼›ç¤¼å±±ï¼ˆEli Lillyï¼‰GLP-1è¯ç‰©é”€å”®é¢„æœŸå¼ºåŠ²ï¼Œå°½ç®¡é¢ä¸´å®šä»·å‹åŠ›ï¼›å®‰è¿›ï¼ˆAmgenï¼‰ç½•è§ç—…è¯ç‰©Tavneosé¢ä¸´FDAæ’¤å¸‚è¦æ±‚ä½†å…¬å¸æ‹’ç»æ‰§è¡Œï¼Œå‡¸æ˜¾ç›‘ç®¡åšå¼ˆã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>1. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - ç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’é‡æ–°æˆæƒè‡³2029å¹´ï¼Œå°†æ˜¾è‘—æ¿€åŠ±å„¿ç§‘ç½•è§ç—…è¯ç‰©ç ”å‘ã€‚</p>
<p><strong>11. Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - ç¤¼å±±GLP-1è¯ç‰©Mounjaroå’ŒZepboundé”€å”®é¢„æœŸå¼ºåŠ²ï¼Œæ˜¯å½“å‰åˆ¶è¯å¸‚åœºæœ€å¤§å¢é•¿å¼•æ“ã€‚</p>
<p><strong>28. FDA seeks withdrawal of Amgen's Tavneos, but company says it won't pull drug</strong> â­â­â­â­<br>
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹<br>
   - FDAè¦æ±‚æ’¤å¸‚ä½†å®‰è¿›æ‹’ç»ï¼Œæ¶‰åŠç½•è§ç—…è¯ç‰©å®‰å…¨æ€§ä¸ç›‘ç®¡æƒå¨çš„ç½•è§å…¬å¼€å¯¹æŠ—ã€‚</p>
<p><strong>15. India will invest $1.1B to boost development of biologics, biosimilars</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - å°åº¦æ”¿åºœå·¨é¢æŠ•èµ„ç”Ÿç‰©è¯ä¸ç”Ÿç‰©ç±»ä¼¼è¯ï¼Œæ ‡å¿—å…¶ä»ä»¿åˆ¶è¯å‘ç”Ÿç‰©åˆ¶è¯çš„æˆ˜ç•¥è½¬å‹ã€‚</p>
<p><strong>3. FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ–°è¯ç ”å‘<br>
   - FDAè¡¨æ€æ”¯æŒCAR-Tç–—æ³•å‘è‡ªèº«å…ç–«ç—…é¢†åŸŸæ‹“å±•ï¼Œé¢„ç¤ºç»†èƒç–—æ³•æ–°å‰æ²¿çš„ç›‘ç®¡è·¯å¾„ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): CAR-Tç–—æ³•å‘è‡ªèº«å…ç–«ç—…æ‹“å±•è·FDAæ”¯æŒï¼›è¯ºå’Œè¯ºå¾·ï¼ˆNovo Nordiskï¼‰CagriSemaç»„åˆç–—æ³•åœ¨ç³–å°¿ç—…è¯•éªŒä¸­è¾¾åˆ°ç›®æ ‡ï¼›FDAæˆäºˆEn Carta Diagnosticsè±å§†ç—…æ£€æµ‹è®¾å¤‡çªç ´æ€§è®¾å¤‡è®¤å®šã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): è¯ºå’Œè¯ºå¾·CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­æ˜¾ç¤ºå‡ºä¼˜äºWegovyçš„é™ç³–å’Œå‡é‡æ•ˆæœï¼›è¾‰ç‘ï¼ˆPfizerï¼‰åœ¨è´¢æŠ¥ä¸­æåŠè‚¥èƒ–ç—‡è¯ç‰©çš„ç§¯ææ•°æ®ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>å…³æ³¨å®‰è¿›ï¼ˆAmgenï¼‰ä¸FDAå°±Tavneosæ’¤å¸‚è¦æ±‚çš„åç»­è¿›å±•ï¼›ç•™æ„å°åº¦ç”Ÿç‰©åˆ¶è¯æŠ•èµ„è®¡åˆ’çš„å…·ä½“å®æ–½ç»†èŠ‚ï¼›ç›‘æµ‹é¦–æ‰¹10ç§Medicareè°ˆåˆ¤è¯å“ä»·æ ¼ç”Ÿæ•ˆåå¯¹æ‚£è€…å®é™…èŠ‚çœçš„å½±å“è¯„ä¼°ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">44 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 15:02</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rising Stars: emagineHealth&#39;s Barbara Leal lives and works by the mantra of â€˜humans first, professionals secondâ€™
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 15:25</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In a Q&amp;amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Leal explained how healthcare and pharma marketing combines the â€œbest of both worldsâ€ for her.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 11:17</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDAâ€™s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible regulatory approach.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/fda-signals-tailored-approach-carefully-shepherd-car-t-therapy-autoimmune-diseases" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company&#39;s momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;amp;J competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie&#39;s immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company&#39;s yearly haul of $61.1 billion.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        As CEO, Luke Miels wants GSK to be more &#39;product-centric&#39;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Amgen resists FDA request to pull rare disease drug Tavneos from the market
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 07:41</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/amgen-resists-fda-request-pull-rare-disease-drug-tavneos-market-0" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        India will invest $1.1B to boost development of biologics, biosimilars
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA rejects AZ&#39;s subQ Saphnelo, but company expects quick turnaround for new approval decision
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 09:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ&#39;s application that would allow patients to self-administer the monoclonal antibody in a prefilled pen. The advancement would give patients a convenient alternative to traveling to a doctor&#39;s office for infusions every four weeks.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        With FDA rejections, Aquestive&#39;s shares go up, while Pharming&#39;s go down
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 11:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-rejections-aquestives-shares-go-while-pharmings-go-down" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 10:02</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fda-emphasizes-drug-ingredients-production-pledges-it-debuts-precheck-manufacturing-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:03</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BMS celebrates US soccer legend&#39;s shutout against cancer in Breyanzi collab
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 11:20</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:47</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BMS, J&amp;amp;J factor in HCP education on clot-busting mechanism before milvexian data drop
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 09:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bristol Myers Squibb and Johnson &amp;amp; Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bms-jj-factor-physician-education-clot-busting-mechanism-x-factor-readouts" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 13:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: Novo shares plummet on sales, profit warning for &#39;26 as 2 top execs head for the doors
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 13:39</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sweden&#39;s Nanologica acquires API facility from CDMO Ardena, brings team of 45 on board
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 08:31</span>
                        
                    </div>
                    
                    <p class="news-summary">Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardenaâ€™s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/swedens-nanologica-acquires-ardenas-syntagon-facility-stock-trade-deal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A &#39;game of inches&#39;: Pfizer channels Al Pacino in World Cancer Day ad
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/pfizer-channels-al-pacino-spirited-world-cancer-day-ad" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS launches $100M antiviral prize to develop broad-spectrum therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 14:39</span>
                        
                    </div>
                    
                    <p class="news-summary">While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Charles River to close cell therapy CDMO site, lay off 20 staffers
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.</p>
                    
                    <a href="https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 11:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As top-selling Keytruda inches closer to its 2028 patent cliff, Merck&#39;s confidence in sustainable growth for the future is &#34;as high as it&#39;s ever been,&#34; CEO Robert Davis said on the company&#39;s full-year 2025 earnings call.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi sanctioned by PMCPA over CEO&#39;s &#39;bold claims&#39; about Pfizer RSV vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-03 05:34</span>
                        
                    </div>
                    
                    <p class="news-summary">A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. governmentâ€™s vaccine program by making â€œbold claimsâ€ about a procurement choice.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie has â€˜Love in Mindâ€™ with new migraine educational campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 12:11</span>
                        
                    </div>
                    
                    <p class="news-summary">With Valentineâ€™s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/abbvie-has-love-mind-new-migraine-educational-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thermo Fisher trims Mass. head count with Franklin site closure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-02 11:06</span>
                        
                    </div>
                    
                    <p class="news-summary">Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site itâ€™s shuttering in Franklin, Massachusetts, which currently employs about 200 people.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/thermo-fisher-trims-massachusetts-headcount-franklin-site-closure" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 18:07</span>
                        
                    </div>
                    
                    <p class="news-summary">The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer defends data on Metsera candidate
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:44</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 17:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer unveils data on Metsera drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:41</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer moves forward with its hopes for a monthly obesity drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: A play takes on Novoâ€™s myth and money
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 14:51</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 13:47</span>
                        
                    </div>
                    
                    <p class="news-summary">Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-02 06:00</span>
                        
                    </div>
                    
                    <p class="news-summary">An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek approval.</p>
                    
                    <a href="https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 17:06</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: New rule would force PBMs to disclose drug rebates and other fees
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 15:48</span>
                        
                    </div>
                    
                    <p class="news-summary">The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.</p>
                    
                    <a href="https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: AstraZeneca looks to China for obesity drug candidates
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-30">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-30 14:35</span>
                        
                    </div>
                    
                    <p class="news-summary">Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: States are the next vaccine battleground
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 17:07</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of STAT&#39;s D.C. Diagnosis newsletter.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-29 16:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Trump wants lawmakers to force pharma companies to lower their prices, but it&#39;s not clear the GOP is on board.</p>
                    
                    <a href="https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rare pediatric PRV program reauthorized until 2029 via government funding law
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 18:27</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">President Donald Trump on Tuesday signed the government funding extension that also reauthorized the FDA&#39;s ability to issue rare pediatric priority reviews through 2029, reviving an incentive program that industry has fought to keep. ...</p>
                    
                    <a href="https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:51</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer took a write-down on one of its recent high-profile acquisitions while reporting a positive readout from another. The pharma giant said on Tuesday it took a $4.4 billion impairment charge related in part to ...</p>
                    
                    <a href="https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:03</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...</p>
                    
                    <a href="https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 20:42</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The first 10 drugs that underwent government price negotiations in 2023 were projected to save the government billions of dollars. Now, one month since the new pricing took effect, the extent to which those savings ...</p>
                    
                    <a href="https://endpoints.news/first-10-medicare-negotiated-drug-prices-have-taken-effect-are-seniors-really-saving-money/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 01:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.</p>
                    
                    <a href="https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 17:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly soars again as fast-selling weight loss drugs top Wall Street projections
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 16:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Despite some angst over pricing pressure for GLP-1 drugs, Lilly&amp;rsquo;s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.</p>
                    
                    <a href="https://www.biopharmadive.com/news/lilly-earnings-guidance-q4-2025-obesity-drugs/811317/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Earnings roundup: Amgen vs. FDA, Pfizerâ€™s defense and Merckâ€™s $70B-in-sales plan
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 14:51</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amgen is refusing U.S. regulators&amp;rsquo; request to&amp;nbsp;withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.</p>
                    
                    <a href="https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA launches â€˜PreCheckâ€™ program; AstraZeneca, Acadia drugs set back
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-03 15:11</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The agency&amp;rsquo;s program will be open to pharmaceutical facilities that align with &amp;ldquo;national priorities.&amp;rdquo; Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.</p>
                    
                    <a href="https://www.biopharmadive.com/news/fda-precheck-astrazeneca-acadia-reject-meiragtx/811092/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo combination obesity shot meets goal in diabetes trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 19:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CagriSema&amp;rsquo;s blood sugar and weight reductions exceeded the company&amp;rsquo;s blockbuster Wegovy, yet the drug might still struggle to rival Lilly&#39;s Zepbound.</p>
                    
                    <a href="https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Veradermics lands $256M IPO for oral Rogaine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Veradermics headed out of the gates with an initial public offering that garnered $256 million in gross proceeds, a bigger-than-expected debut that suggests investors may be hungry for a rebound in biotech listings. Veradermics, which ...</p>
                    
                    <a href="https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Hims adds Grail&#39;s cancer test amid questions about widespread use
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Hims &amp;amp; Hers is bringing Grail&#39;s cancer test to its consumer health platform, marking a significant step toward mass adoption of a technology that&#39;s shown progress while remaining under scientific debate. Grail, a pioneer in ...</p>
                    
                    <a href="https://endpoints.news/hims-adds-grails-cancer-test-amid-questions-about-widespread-use/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novartis says generics to erode $4B from 2026 sales
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 12:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis said further generic erosion of three blockbuster medicines, including its top-selling heart failure drug Entresto, will leave a $4 billion hole in its sales this year. Generic competition started to make a mark in ...</p>
                    
                    <a href="https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA seeks withdrawal of Amgen&#39;s Tavneos, but company says it won&#39;t pull drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 00:48</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Several years of questions about Amgen&#39;s rare disease treatment Tavneos have reached a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans to ...</p>
                    
                    <a href="https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UKâ€™s health department expected to spend Â£1B in pharma trade deal with US
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 00:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The UK&#39;s drug pricing deal with the White House is expected to cost Â£1 billion between 2026 and 2029, according to a letter from the country&#39;s science minister. The letter was published Wednesday morning by ...</p>
                    
                    <a href="https://endpoints.news/uks-health-department-expected-to-spend-1b-in-pharma-trade-deal-with-us/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s driving health tech M&amp;A
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 16:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The past week saw a flurry of health tech acquisitions (we counted at least five!). Part of the rush of activity is seasonal â€” the end of the year often serves as a ...</p>
                    
                    <a href="https://endpoints.news/whats-driving-health-tech-ma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China startup AccurEdit raises $75M for gene editing therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 16:13</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines â€” among the largest rounds on record for a Chinese gene editing ...</p>
                    
                    <a href="https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ultragenyx unwraps data that may be central to its gene therapy resubmission
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 13:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Ultragenyx outlined new data on Tuesday that it hopes will convince the FDA to approve its recently resubmitted rare disease gene therapy. Among 17 patients with Sanfilippo syndrome type A who received the therapy, cognition ...</p>
                    
                    <a href="https://endpoints.news/ultragenyx-unwraps-data-that-may-be-central-to-its-gene-therapy-resubmission/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Do Pfizerâ€™s monthly GLP-1 data justify Metseraâ€™s $10B price tag?
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on ...</p>
                    
                    <a href="https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer dips on new data for obesity drug acquired in $10B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-03 17:01</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A long-acting shot Pfizer got through a buyout of Metsera appeared &amp;ldquo;slightly inferior&amp;rdquo; to Lilly&amp;rsquo;s market-leading Zepbound in a Phase 2 trial, one analyst said.</p>
                    
                    <a href="https://www.biopharmadive.com/news/pfizer-obesity-metsera-phase-2-results-GLP1-monthly-shot/811201/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo shares tumble by double digits on grim sales outlook
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 16:55</span>
                        
                    </div>
                    
                    <p class="news-summary">In contrast to Lilly&amp;rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 17:12</span>
                        
                    </div>
                    
                    <p class="news-summary">The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.</p>
                    
                    <a href="https://www.biopharmadive.com/news/sanofi-venglustat-gaucher-fabry-study-results/811113/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK walks away from pioneering Wave RNA editing drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-02 13:31</span>
                        
                    </div>
                    
                    <p class="news-summary">Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wave-gsk-reacquire-rna-editing-drug-aatd/811067/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FTC settles insulin lawsuit with Express Scripts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 20:49</span>
                        
                    </div>
                    
                    <p class="news-summary">The FTC has settled with Express Scripts over its use of insulin rebates, securing an agreement that stretches across almost every corner of the company&#39;s business model. The commission and Express Scripts</p>
                    
                    <a href="https://endpoints.news/ftc-settles-insulin-lawsuit-with-express-scripts/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie says immunology blockbusters will be &#39;main drivers&#39; of growth post-Humira
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 20:40</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/abbvie-says-immunology-blockbusters-will-be-main-drivers-of-growth-post-humira/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSKâ€™s new CEO eyes more dealmaking, intense pipeline inspection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 15:01</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK CEO Luke Miels laid out the drugmakerâ€™s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir. â€œWe need ...</p>
                    
                    <a href="https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Midi Health raises $100M as it plans expansion into urgent care, research
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 14:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Health techâ€™s latest unicorn is Midi Health, a womenâ€™s health startup launched during the pandemic that has since expanded into broader virtual care with a recent focus on longevity. The startup hit ...</p>
                    
                    <a href="https://endpoints.news/midi-health-raises-100m-as-it-plans-expansion-into-urgent-care-research/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 12:10</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly surpassed analysts&#39; expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects ...</p>
                    
                    <a href="https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-04 10:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer&#39;s monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has ...</p>
                    
                    <a href="https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo expects sales to fall in 2026, triggering selloff
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 20:07</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk expects its sales to shrink by at least 5% this year, citing negative pricing dynamics, including its deal with the US government. The Danish pharma said in its</p>
                    
                    <a href="https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        &#39;Turning around the Titanic&#39;: How the incoming PBM reforms will transform CMS
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 19:34</span>
                        
                    </div>
                    
                    <p class="news-summary">The Centers for Medicare and Medicaid Services has never played a significant role in regulating pharmacy benefit managers, the middlemen that have historically relied on high drug prices for profits. But the government spending package ...</p>
                    
                    <a href="https://endpoints.news/turning-around-the-titanic-how-the-incoming-pbm-reforms-will-transform-cms/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Daiichi ends work on an ADC; Layoffs at GSK&#39;s R&amp;D unit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 15:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, SantÃ© Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics and Newsoara: âœ‚ï¸ Daiichi Sankyo culls next-gen ADC: Citing a strategic portfolio review ...</p>
                    
                    <a href="https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Menlo and a16z back AI scientist startup Phylo
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-03 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Within days of defending their PhDs last year, two Stanford University researchers incorporated their own startup, betting they could build a business around their AI system that handles scientific tasks. The Bay Area startup, called ...</p>
                    
                    <a href="https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Carbon Health files for bankruptcy, seeking to sell or restructure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-02 21:22</span>
                        
                    </div>
                    
                    <p class="news-summary">Carbon Health has filed for bankruptcy protection and is seeking to restructure or sell itself, the urgent and primary care startup said Monday. The company voluntarily filed for Chapter 11 in the US Bankruptcy Court ...</p>
                    
                    <a href="https://endpoints.news/carbon-health-files-for-bankruptcy-seeking-to-sell-or-restructure/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Understanding the Risks of Compounded Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 20:18</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:35</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        PDUFA VIII: Fiscal Years 2028 â€“ 2032
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 22:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Information related to FDAâ€™s preparation for the seventh reauthorization of PDUFA.</p>
                    
                    <a href="http://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-viii-fiscal-years-2028-2032" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 21:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 21:41</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        About CDER Small Business and Industry Assistance (SBIA)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CDER Small Business and Industry Assistance (SBIA) helps small pharmaceutical business and industry navigate the wealth of information that FDA offers, and provides assistance in understanding the regulation of human drug products.</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/about-cder-small-business-and-industry-assistance-sbia" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novel Drug Approvals for 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 21:41</span>
                        
                    </div>
                    
                    <p class="news-summary">Innovative drugs often mean new treatment options for patients and advances in health care for the American public.</p>
                    
                    <a href="http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots: WAYRILZ
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 21:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: WAYRILZ</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-wayrilz" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Withdrawn and Expired Guidances | Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Withdrawn and Expired Guidances | Drugs</p>
                    
                    <a href="http://www.fda.gov/drugs/guidances-drugs/withdrawn-and-expired-guidances-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:50</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GDUFA Type II API DMF Payment Receipts Report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:46</span>
                        
                    </div>
                    
                    <p class="news-summary">GDUFA Type II API DMF Payment Receipts Report</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/gdufa-type-ii-api-dmf-payment-receipts-report" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:45</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Compounding Quality Center of Excellence | Instructor-Led Trainings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 18:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.</p>
                    
                    <a href="http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots: REDEMPLO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:54</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: REDEMPLO</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-redemplo" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Stay Informed about Small Business
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:51</span>
                        
                    </div>
                    
                    <p class="news-summary">Stay Informed about Small Business</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/stay-informed-about-small-business" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CDER Small Business and Industry Assistance (SBIA) Learn
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:49</span>
                        
                    </div>
                    
                    <p class="news-summary">SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Health Fraud Scams
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Learn how to spot health fraud and avoid it.</p>
                    
                    <a href="http://www.fda.gov/consumers/health-fraud-scams" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots: LEROCHOL
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:36</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: LEROCHOL</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lerochol" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CDER Small Business &amp; Industry Assistance (SBIA)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:12</span>
                        
                    </div>
                    
                    <p class="news-summary">A Comprehensive Resource for Information on Human Drug Development in Regulation</p>
                    
                    <a href="http://www.fda.gov/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots: REDEMPLO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-04 16:12</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: REDEMPLO</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-redemplo-0" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:18</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The US sees around 476,000 new Lyme cases every year</p>
                    
                    <a href="https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IBSA UK&amp;I launches Perovial for the treatment of acute Peyronieâ€™s disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease</p>
                    
                    <a href="https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CERo reports encouraging early data from phase 1 trial of CERâ€‘1236
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:59</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CERâ€‘T therapy shows initial safety signals and prompts protocol expansion</p>
                    
                    <a href="https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-29">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-29 10:44</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections</p>
                    
                    <a href="https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thomas Farrell
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:48</span>
                        
                    </div>
                    
                    <p class="news-summary">NanoSyrinx has appointed Thomas Farrell as CEO and Director</p>
                    
                    <a href="https://pharmatimes.com/appointments/thomas-farrell/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ahmed Moussa
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Ahmed Moussa is the new Sanofi Country Lead for UK &amp;#038; Ireland</p>
                    
                    <a href="https://pharmatimes.com/appointments/ahmed-moussa/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:43</span>
                        
                    </div>
                    
                    <p class="news-summary">The company will initially develop a vaccine to tackle colorectal and pancreatic cancers</p>
                    
                    <a href="https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys</p>
                    
                    <a href="https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-02-05 04:14</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>